Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2000-3-23
pubmed:abstractText
From 8,419 worldwide clinical isolates of Streptococcus pneumoniae obtained during 1997-1998, 69 isolates with reduced susceptibility or resistance to fluoroquinolones (FQs) were molecularly characterized. For the isolates in this prevalence study, only parC (Ser-79-->Tyr) and gyrA (Ser-81-->Phe or Tyr) mutations, especially in combination, were found to contribute significantly to resistance. These mutations influenced the FQ MICs to varying degrees, although the rank order of activity remains independent of mutation type, with ciprofloxacin the least active, followed by levofloxacin, gatifloxacin/grepafloxacin/moxifloxacin/sparfloxaci n/trovafloxacin, and clinafloxacin/sitafloxacin. Efflux likely plays a crucial role in reduced susceptibility for new hydrophilic FQs.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-10052906, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-10413735, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-1332587, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-1503449, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-1854167, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8139650, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8723468, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8763932, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8891124, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8891138, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8913454, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-8957575, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9124824, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9124836, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9145891, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9458982, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9593159, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9593165, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9593169, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9603872, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9687402, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9736534, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9797208, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9798031, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9869592, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9925523, http://linkedlifedata.com/resource/pubmed/commentcorrection/10639387-9925527
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
462-6
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.
pubmed:affiliation
MRL Pharmaceutical Services, Utrecht, The Netherlands. mjones@thetsn.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't